# First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

> **NCT00981058** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1093 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Necitumumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00981058
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-07
- **Primary completion:** 2013-06-17
- **Final completion:** 2024-05-30
- **Target enrollment:** 1093 (ACTUAL)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981058, "First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00981058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*